Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

PURPOSE: Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy in HER2 + breast cancer models with other PI3K inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiascarelli, Alessio, Merlino, Giuseppe, Capano, Stefania, Talucci, Simone, Bisignano, Diego, Bressan, Alessandro, Bellarosa, Daniela, Carrisi, Corrado, Paoli, Alessandro, Bigioni, Mario, Tunici, Patrizia, Irrissuto, Clelia, Salerno, Massimiliano, Arribas, Joaquin, de Stanchina, Elisa, Scaltriti, Maurizio, Binaschi, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147754/
https://www.ncbi.nlm.nih.gov/pubmed/36913051
http://dx.doi.org/10.1007/s10549-023-06895-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147754/
https://www.ncbi.nlm.nih.gov/pubmed/36913051
http://dx.doi.org/10.1007/s10549-023-06895-2

Ejemplares similares